FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 793 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC... June 30, 2023 Sister Is There To Comfort Her Little Brother As He Battles... September 10, 2019 Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline... March 29, 2023 Obesity May Help Tumors Survive and Grow, Mouse Study Suggests January 22, 2021 Load more HOT NEWS Why Have Thyroid Cancer Diagnoses Spiked for US Women? Pediatricians’ Offices Can Help Parents Quit Smoking, Study Shows FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily...
